Expanded low allele frequency RAS and BRAF V600E testing in metastatic colorectal cancer as predictive biomarkers for cetuximab in the randomized CO.17 trial

BACKGROUND: Expanded RAS/BRAF mutations have not been assessed as predictive for single-agent cetuximab in metastatic colorectal cancer (mCRC) and low mutant allele frequency (MAF) mutations are of unclear significance. We aimed to establish cetuximab efficacy in optimally selected patients using hi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Loree, Jonathan M., Dowers, Anthony, Tu, Dongsheng, Jonker, Derek J., Edelstein, Daniel L., Quinn, Hannah, Holtrup, Frank, Price, Timothy, Zalcberg, John R., Moore, Malcolm J., Karapetis, Christos S., O’Callaghan, Chris J., Waring, Paul, Kennecke, Hagen F., Hamilton, Stanley R., Kopetz, Scott
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7785657/
https://ncbi.nlm.nih.gov/pubmed/33087330
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-2710
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia